Precision Health AI

Precision Health AI, also known as PH.AI and Precision Health Intelligence, was an oncology-focused artificial intelligence platform technology company that has since evolved into ConcertAI. The company was founded in New York by Brigham Hyde, Ph.D., a research affiliate at MIT and lecturer at Tufts University with a background in clinical pharmacology and experience in preclinical drug development. In September 2017, the firm emerged from stealth with a significant $20 million Series A investment led by the SymphonyAI Group.

The company's primary focus was on applying AI to the field of oncology. It served a diverse client base that included pharmaceutical and life sciences companies, healthcare providers, and payers. The business model revolved around providing data, software applications, and access to its proprietary AI platform, which was named the Eureka Health Oncology AI Platform. This platform was designed to analyze real-world data (RWD) to accelerate drug development, enhance clinical trials, and provide evidence for the broader cancer care ecosystem.

Precision Health AI's core service was its AI platform that processed deep, longitudinal patient data sourced from Electronic Medical Records (EMR), insurance claims, and various diagnostic sources. Through a partnership with the American Society of Clinical Oncology's (ASCO) CancerLinQ program, the company aggregated and de-identified vast amounts of clinical data, including radiology and genomics information. The Eureka Health platform featured over 60 pretrained and learning-enhanced modules specifically designed for oncology. These modules could predict patient outcomes, identify potential adverse drug reactions like chemotherapy-induced neutropenia, and match patients to clinical trials, thereby aiming to provide data-driven, evidence-based decision-making support.

Precision Health AI was a predecessor to ConcertAI, where founder Brigham Hyde also played a co-founding and operational role. ConcertAI continued the mission of leveraging real-world evidence and AI, eventually acquiring the CancerLinQ entity from ASCO in late 2023. Brigham Hyde has since transitioned to become the CEO and co-founder of Atropos Health. Keywords: precision oncology, artificial intelligence, real-world data, cancer research, healthcare data, pharmaceutical services, clinical trial optimization, oncology analytics, EMR data analysis, patient outcome prediction, value-based care, health tech, Brigham Hyde, SymphonyAI, ConcertAI, CancerLinQ, Eureka Health platform, life sciences, HEOR studies, RWD solutions